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ABSTRACT 
Objective The use of herbal medicines for induction of 
labour (IOL) is common globally and yet its effects are not 
well understood. We assessed the eficacy and safety of 
herbal medicines for IOL.
Design Systematic review and meta-analysis of published 
literature.
Data sources We searched in MEDLINE, AMED and 
CINAHL in April 2017, updated in June 2018.
Eligibility criteria We considered experimental and non-
experimental studies that compared relevant pregnancy 
outcomes between users and non-user of herbal 
medicines for IOL.
Data extraction and synthesis Data were extracted 
by two reviewers using a standardised form. A random-
effects model was used to synthesise effects sizes and 
heterogeneity was explored through I2 statistic. The risk 
of bias was assessed using ‘John Hopkins Nursing School 
Critical Appraisal Tool’ and ‘Cochrane Risk of Bias Tool’.
Results A total of 1421 papers were identiied through 
the searches, but only 10 were retained after eligibility and 
risk of bias assessments. The users of herbal medicine 
for IOL were signiicantly more likely to give birth within 
24 hours than non-users (Risk Ratio (RR) 4.48; 95% CI 
1.75 to 11.44). No signiicant difference in the incidence 
of caesarean section (RR 1.19; 95% CI 0.76 to 1.86), 
assisted vaginal delivery (RR 0.73; 95% CI 0.47 to 1.14), 
haemorrhage (RR 0.84; 95% CI 0.44 to 1.60), meconium-
stained liquor (RR 1.20; 95% CI 0.65 to 2.23) and 
admission to nursery (RR 1.08; 95% CI 0.49 to 2.38) was 
found between users and non-users of herbal medicines 
for IOL.
Conclusions The indings suggest that herbal medicines 
for IOL are effective, but there is inconclusive evidence of 
safety due to lack of good quality data. Thus, the use of 
herbal medicines for IOL should be avoided until safety 
issues are clariied. More studies are recommended to 
establish the safety of herbal medicines.
INTRODUCTION
Across the world, the use of unconventional or 
traditional medical therapies is very high.1–4 
These non-biomedical remedies are together 
referred to as complementary and alternative 
medicines (CAMs). WHO recognises the role 
of CAM of verified quality, safety and efficacy 
in ensuring universal access to healthcare.5 As 
such, for the period between 2014 and 2023, 
WHO traditional medicine strategy focuses 
on harnessing the potential contribution of 
CAM in healthcare and promoting its safe and 
effective use.5 Although this requires rigorous 
evidence on safety and efficacy of CAM, 
research in this area remains limited.5 Herbal 
medicine or medicinal plant is one of the 
well-known CAM therapies that involve the 
use of plants or plant extracts for therapeutic 
motives.6 As in the general population, the 
use of herbal medicines is common among 
pregnant women globally.7–10 The estimated 
prevalence varies between regions and coun-
tries but ranges from 10% to 80%.11 12 One of 
the common indications for herbal medicine 
use during pregnancy is prolonged labour 
or merely the desire to induce or augment 
labour for different reasons.13 14 This practice 
is well documented and transcends cultural 
and generational boundaries.14 
From a medical perspective, induction 
of labour (IOL) changes the physiological 
processes associated with childbirth in ways 
that may increase the risk of adverse preg-
nancy outcomes such as neonatal mortality, 
fetal distress, premature birth, haemorrhage, 
Strengths and limitations of this study
 Ź Due to safety and ethical reasons, herbal med-
icines for pregnant women are rarely evaluated 
through randomised controlled/clinical trials (RCTs). 
Nonetheless, most of the reviews of herbal medi-
cines during pregnancy are restricted to RCTs. The 
present review included non-experimental studies to 
assess a wider evidence base.
 Ź No restrictions were applied on the date of publica-
tion, location, study design and types of treatment 
(herbal medicine used).
 Ź There is lack of data on key outcomes (eg, maternal 
death and sepsis) and from low-income countries.
 Ź Some analyses did not have suficient statistical 
power due to the inadequate number of studies and 
small sample sizes.
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uterine rupture and caesarean section.15–17 Because 
of this, WHO recommends that labour should only be 
induced in health facilities with the capacity for continual 
monitoring and emergency obstetric care.18 The emphasis 
on facility-based IOL and close monitoring of pregnant 
women demonstrates the risks associated with the proce-
dure. Nonetheless, with herbal medicine-induced labour, 
monitoring of women is often out of the question due to 
self-prescription.2 19 So, the use of herbal medicines for 
IOL is likely to be riskier and it is plausibly an important 
factor influencing adverse pregnancy outcomes in settings 
where its use is common.
In vitro studies have confirmed that some of the herbal 
medicines used during pregnancy have oxytocic proper-
ties.13 20 For instance, a study in Nigeria found that several 
plants that are used to facilitate childbirth in the country 
significantly induced muscle cell contractility.13 However, 
safety is the main concern as many of the herbal medi-
cines are believed to be poisonous and may contribute to 
maternal and neonatal mortality as well as morbidity.21 22 
To date, there is mixed evidence from population-based 
studies regarding the efficacy and safety of herbal medi-
cines for IOL23–25 and yet available data have not been 
systematically evaluated and synthesised to provide the 
rigorous evidence necessary to inform decisions. Lack 
of high quality and consistent data on efficacy and safety 
of herbal medicines makes recommendations and regu-
lations challenging.5 Consequently, we conducted a 
systematic review to explore the effectiveness and safety 
of herbal medicines for IOL. This review is important to 
inform the development of guidelines relating to the use 
of herbal medicines among pregnant women.
METHODS
Design
This is a systematic review and meta-analysis of published 
literature on effectiveness and safety of herbal medicines 
for IOL. The reporting of the abstract (online supple-
mentary file S1) and results (online supplementary file 
S2) are guided by the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses .26
Data sources and searches
We searched in MEDLINE, AMED and CINAHL from 13 
February to 22 April 2017 and repeated this on 22 June 
2018 using key terms such as herbal medicine, labour and 
pregnancy outcomes, which were modified in accordance 
with each database (online supplementary file S3). More 
papers were identified through scanning the reference 
list of studies found through the initial search as well as 
direct searches in the following journals: African Journals 
Online, Journal for Herbal Medicine, BMC Complemen-
tary and Alternative Medicine, Journal of Alternative and 
Complementary Medicine and Journal of Integrative 
Medicine.
Inclusion/exclusion criteria
The inclusion criteria were based on participant, inter-
vention, control, outcomes and studies. We considered 
studies with pregnant or postpartum women as partici-
pants. The treatment or exposure was herbal medicines 
for induction or shortening of labour. For studies that did 
not explicitly indicate the reasons for use, the name of the 
medicine was used to determine if IOL was the possible 
motive. There was no restriction on dosage, but the route 
of administration was oral. The plants could be either 
processed or crude and used alone or alongside conven-
tional medicines. An appropriate comparison group 
comprised either pregnant women who did not use the 
herbal medicine under consideration or used biomedical 
drugs exclusively. The maternal outcomes were haemor-
rhage, sepsis, caesarean section, uterine rupture, assisted 
vaginal delivery and maternal death; while the neonatal 
outcomes were stillbirth, premature birth, neonatal 
mortality, meconium-stained liquor (MSL)/fetal distress, 
birth defects and referral to neonatal intensive care unit 
(also known as nursery).
Due to ethical, safety  and methodological 
issues, pregnant women are often excluded from 
randomised controlled/clinical trials (RCTs) and herbal 
medicines may not be evaluated through RCTs.27–29 Thus, 
observational studies are a common source of litera-
ture for efficacy and safety of herbal medicines in preg-
nancy. Accordingly, we considered both experimental 
and non-experimental study designs. In particular, the 
following study designs were eligible for inclusion: RCTs, 
quasi-experimental, cohort, case–control and cross-sec-
tional. We only considered studies published in English 
or in other languages, but with a detailed English abstract. 
No restrictions were applied on the date of publication 
and study setting.
Data extraction
A data extraction form (online supplementary file 
S4) was developed specifically for this review based on 
templates developed by the Joanna Briggs Institute and 
the Cochrane Pregnancy and Childbirth Group.30 31 The 
form included specific details about the study design, 
participants, setting, intervention/exposure, control 
and outcomes. Owing to the focus of our study (ie, effi-
cacy and safety), ‘per protocol’ treatment effects were 
preferred in RCTs.32 As none of the observational studies 
reported adjusted effect estimates, crude data were 
extracted and used in this review. Two reviewers—CZ and 
CM—separately extracted the data and any differences 
were resolved by discussion.
Quality/risk of bias assessment
Two different tools were used to assess the risk of bias in 
experimental and non-experimental studies that met the 
inclusion criteria. CZ and CM independently performed 
the risk of bias assessment and any disagreements 
were resolved by discussion. For experimental studies, 
Cochrane Risk of Bias tool for the RCTs33 was used and 
the following domains were assessed: random sequence 
generation, allocation concealment, blinding of partic-
ipants, blinding of outcome assessment, incomplete 
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outcome data, selective reporting and other biases 
(online supplementary file S5). Only abstracts were avail-
able in English for two studies25 34 and hence their risk 
of bias is largely unclear. The overall risk of bias for the 
other RCTs is low.
The risk of bias for non-experimental studies was assessed 
using a standardised critical appraisal tool developed by 
‘John Hopkins Nursing School’.35 This tool divides the 
strength of research evidence into five levels based on 
the study design. The RCTs occupy the top level (level I) 
followed by quasi-experimental studies (level II) and other 
non-experimental studies (level III). The last two levels 
are for opinion-related papers either based on research 
evidence (level IV) or individual expertise (level V). The 
quality of evidence is further graded as high (A), good (B) 
and low quality or major flaws (C) depending on the risk of 
bias and scientific basis for the conclusions. Based on this 
tool, a list of 10 questions (or domains) was developed to 
guide the assessment (online supplementary file S6). Since 
the review used crude data, the need to control extraneous 
variables and whether this was done (if required) were key 
factors in determining the study grade. For instance, grade 
C was given to studies in which the treatment and control 
groups were not comparable and confounders were not 
adjusted for. Two studies23 36 received a grade of C and were 
eventually excluded from the review.
Data analysis
Meta-analyses were performed to compare the onset of 
labour (effectiveness) and the incidence of adverse preg-
nancy outcomes (safety) between the users and non-users 
of herbal medicines for IOL. As variations were expected 
between studies due to the differences in setting, design 
and types of herbal medicines, a random-effects model 
was used to synthesise effects sizes of the studies.37 
Heterogeneity was explored through the I2 statistic and 
meta-analysis was conducted regardless of the outcome as 
random-effects model accommodates statistical heteroge-
neity.38 Subject to availability of the sufficient number of 
studies, subgroup analyses were conducted based on the 
type of treatment/exposure or study design to explain 
observed heterogeneity. Potential publication bias was 
assessed using Egger’s test since all analyses had less than 
10 studies to use a funnel plot method.39 40 Summary 
effects were measured using risk ratios (RRs) and all anal-
yses were performed using Stata/SE V.13.1 software.
Patient and public involvement
As this was a review of existing literature, we did not 
involve any patient and the public in the design and 
conduct of the study. However, the development of the 
review question was informed by the experiences of preg-
nant women as observed in the literature.
RESULTS
Study selection process
Searches in the three databases returned a total of 1421 
papers (CINAHL=420, AMED=279 and MEDLINE=723). 
After removal of duplicates (n=539), the titles and/
or abstracts of 882 publications were screened and 802 
studies were dropped at this stage for various reasons (see 
figure 1). Full-text articles were retrieved for 80 studies 
for further eligibility assessment and 71 of them failed to 
meet the inclusion criteria. Additional potential relevant 
papers (n=3) were identified through direct searches in 
journals and reference lists. Twelve papers were appraised 
in the final stage and two were excluded due to poor 
methodological quality (see online supplementary file 
S6). Thus, 10 studies were included in this review.
An overview of the included studies
Online supplementary file S7 presents the characteristics 
of the studies, such as location, exposure, outcomes and 
ratings. In brief, of the 10 studies in the review, three were 
conducted in Iran, two in the USA and one each in South 
Africa, Israel, Thailand, Australia and Italy. In relation to 
the World Bank’s classification of countries by income, 
half of the studies were conducted in high-income coun-
tries and the other half in upper-middle-income countries 
(UMICs). No study from low-income countries (LICs) or 
lower-middle-income countries (LMICs) was included.
Three types of exposures were reported by the studies. 
An Australian study was concerned with exposure to 
raspberry leaf.41 This is one of the common herbal reme-
dies used during pregnancy that is believed to prepare 
the uterus for childbirth and thereby effectively reduce 
the length of labour.14 In this study, exposure was self-re-
ported by the participants as they were given raspberry 
pills by the nurses to take at home. Eight studies exam-
ined exposure to castor oil.25 34 42–47 The oil is derived 
from the castor plant’s bean and is widely thought to 
have oxytocic properties.44 45 In all the studies, pregnant 
women consumed 60 mL of castor oil, but in one study43 
the treatment was repeated in women who did not deliver 
within 1 week after the first dose. One study48 assessed 
general exposure to herbal medicines, but there are indi-
cations in the report that they were for IOL.
Five of the included studies are RCTs and the 
remaining five are non-experimental, including cohort 
(3), case–control (1) and quasi-experimental (1) designs. 
The following pregnancy outcomes were reported by 
the included studies: onset of labour within 24 hours, 
caesarean section, haemorrhage, neonatal referral to 
nursery care, MSL, assisted vaginal delivery, stillbirth, 
neonatal death, maternal death and uterus rupture.
Outcome 1: onset of labour within 24 hours
Eight studies explored the onset of labour within 24 hours 
after the use of herbal medicine for IOL. Castor oil was 
the exposure or intervention in all the studies. As shown 
in figure 2, herbal medicine users were significantly 
more likely to give birth within 24 hours than non-users 
(RR 3.46; 95% CI 1.58 to 7.55). In the subgroup anal-
ysis by study design, similar results were observed among 
experimental studies, but there was no significant differ-
ence in onset of labour between users and non-users 
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among the non-experimental studies (online supplemen-
tary file S8). Publication bias was not an issue (bias 3.23; 
95% CI 0.48 to 5.97), but heterogeneity was significant 
(I2=90.2%, p≤0.001) and this was likely due to variations 
in study design and or setting.
Outcome 2: incidence of caesarean section
The association between herbal medicine use and occur-
rence of caesarean section was examined by six studies. A 
meta-analysis (figure 3) found no significant difference 
in the rate of caesarean section between the users and 
non-users of herbal medicines (RR 1.19; 95% CI 0.76 to 
1.86). Similar results were observed in subgroup analysis 
by type of treatment (online supplementary file S9) and 
study design (online supplementary file S10), except that 
Mabina et al48 (eg, any exposure), found a significant 
difference in the incidence of caesarean section between 
the study groups. Both heterogeneity (I2=45.6%; p=0.102) 
and publication bias were not significant (Bias=−0.39; 
95% CI −4.47 to 3.70).
Outcome 3: incidence of assisted vaginal delivery
In this review, assisted vaginal delivery was defined as 
the use of medical interventions such as forceps and 
or episiotomy to aid delivery. This outcome was reported 
by five studies and a meta-analysis (figure 4) found no 
significant difference between the users and non-users 
of herbal medicines (RR 0.73; 95% CI 0.47 to 1.14). 
Heterogeneity was significant (I2=74.4%; p=0.004), but 
publication bias was not (Bias=−1.87; 95% CI −6.12 to 
2.38). Subgroup analyses by type of treatment (online 
supplementary file S11) and study design (online 
supplementary file S12) did not substantially change the 
results.
Figure 1 A PRISMA low diagram summarising the study selection process. IOL, induction of labour; PRISMA, Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses.
Protected by copyright.
 o
n
 Septem
ber 25, 2019 at The Librarian J B M
orrell Library.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-022499 on 17 October 2018. Downloaded from 
5Zamawe C, et al. BMJ Open 2018;8:e022499. doi:10.1136/bmjopen-2018-022499
Open access
Outcome 4: incidence of haemorrhage
The occurrence of haemorrhage among users and 
non-users of herbal medicines for IOL was assessed by 
four studies and a meta-analysis (figure 5) shows no signif-
icant difference between the two groups (RR 0.84; 95% 
CI 0.44 to 1.60). These results were consistent with those 
in subgroup analyses by type of treatment (online supple-
mentary file S13) as well as study design (online supple-
mentary file S14). Heterogeneity was almost non-existent 
(I2=0.0%; p=0.802) and publication bias was not signifi-
cant (Bias 0.49; 95% CI −2.73 to 3.70).
Outcome 5: incidence of MSL
The occurrence of MSL, a strong indicator of fetal 
distress,49 was reported by five studies. Overall, there is no 
significant difference in the rate of MSL between users 
and non-users of herbal medicines (RR 1.20; 95% CI 0.65 
to 2.23) (figure 6). Comparable results were observed in 
subgroup analysis by type of treatment (online supple-
mentary file S15). However, in subgroup analysis by 
study design, the experimental studies tended to favour 
treatment while the non-experimental inclined towards 
control, but both results were not statistically significant 
(online supplementary file S16). Publication bias was 
not significant (Bias=−2.38; 95% CI −6.76 to 2.00), but 
heterogeneity was high (I2=77.9%; p=0.001) probably due 
to variations across studies.
Outcome 6: neonates’ admission to nursery
Whether a newborn child is referred to neonatal intensive 
care unit (also known as nursery) or not is often used as 
an indicator for well-being.41 This outcome was reported 
by three studies and none of them individually found a 
significant difference in admission to nursery between 
users and non-users of herbal medicines for IOL. A 
meta-analysis (figure 7) found no significant difference 
between the two groups (RR 1.08; 95% CI 0.49 to 2.38). 
Both publication bias (bias=−1.51; 95% CI −7.66 to 4.64) 
and heterogeneity (I2=0.0%; p=0.482) were not signif-
icant. Subgroup analysis was not performed due to the 
inadequate number of studies.
Other outcomes
The following outcomes were either reported by a single 
study or there was insufficient data and hence meta-anal-
yses were not performed: maternal death, stillbirth 
Figure 3 The use of herbal medicines for induction of labour and the incidence of caesarean section. RR, risk ratio.
Figure 2 The use of herbal medicines for induction of labour and onset of labour. RR, risk ratio.
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and uterine rupture. A single study assessed maternal 
death and stillbirth outcomes among users (n=205) and 
non-users (n=407) of castor oil to induce labour.43 No 
maternal death occurred in either group, but one case 
of stillbirth (0.3%) was reported in the control group. 
Uterine rupture was reported by two studies in relation to 
castor oil and only one case was reported among exposed 
women in one of the studies.43 47 Overall, no study found 
a significant difference in any of the three outcomes 
between users and non-users of herbal medicines for IOL.
DISCUSSION
We have found that herbal medicines for IOL are effec-
tive and there is no concrete evidence of association 
with adverse outcomes. On efficacy, we have found that 
women who used the herbal medicines were signifi-
cantly more likely to give birth within 24 hours than their 
counterparts who did not use. This corroborates many 
in vitro studies around the world that have shown that 
some herbal medicines effectively induce uterine contrac-
tions.13 20 50 For instance, studies in Malawi and Nigeria 
have established that some medicinal plants commonly 
prescribed by traditional healers to induce childbirth 
have oxytocic properties.13 20 Previous reviews, however, 
found insufficient evidence for the effectiveness of herbal 
medicines for IOL.51 52 This contradiction could be as a 
result of the differences in inclusion criteria. Most of the 
related reviews excluded non-experimental studies,51 52 
which are a common source of efficacy data due to safety 
issues surrounding RCTs for herbal medicines or preg-
nant women.27 28 53 Whereas this allowed us to assess a 
wider evidence base than the previous reviews, we are also 
mindful of the biases inherent in observational studies. 
Therefore, a definite conclusion about the efficacy of 
Figure 4 The use of herbal medicines for induction of labour and the incidence of assisted vaginal delivery. RR, risk ratio.
Figure 5 The use of herbal medicines for induction of labour and the incidence of haemorrhage. RR, risk ratio.
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herbal remedies for IOL cannot be put forward based on 
the present review.54–56
On safety, we did not find any statistically significant 
difference in the rate of haemorrhage, caesarean section, 
assisted vaginal delivery, referral to neonatal intensive 
care unit, MSL, maternal death, stillborn and uterine 
rupture between participants in treated and control 
groups. The implication is that herbal medicines for IOL 
may not be harmful to women or neonates. This observa-
tion is consistent with the results that have been reported 
by other reviews on a related topic.51 52 Notwithstanding, 
caution must be exercised in the interpretation of this 
data because in some outcomes (eg, caesarean section) 
the difference in the number of cases between treated 
and control groups was very high. This was also noted by 
Boltman-Binkowski51 in her review. Despite lack of statis-
tical significance, she argues that a higher number of 
adverse outcomes among women who ingested castor oil 
implies that the link between the two cannot be entirely 
dismissed. The finding may also be inconclusive owing 
to lack of data on key outcomes, such as maternal death, 
sepsis and neonatal death.
The results of this review should be considered in the 
context of the following limitations and biases. First, 
although the baseline characteristics of the observational 
studies were similar across study groups, not all potential 
confounders were measured. Likewise, of the five RCTs in 
this review, three were unclear on selection, performance 
and detection biases while two had unclear attrition, 
reporting and other biases. Thus, the risk of bias may have 
been introduced as a result of these poor methodologies. 
In addition, some analyses lacked adequate statistical 
power because of small sample sizes or the insufficient 
number of studies. These issues strongly suggest that 
the outcomes of this review be treated with considerable 
caution.
Second, in almost all the studies, herbal remedies were 
provided at the health facility and pregnant women were 
somewhat monitored by clinical staff. In this way, many 
potential adverse events may have been averted or less-
ened. Nevertheless, this does not entirely represent the 
reality of the context in which herbal medicines are taken, 
and thus, the results of these studies may be misleading. 
In sub-Saharan Africa, for instance, herbal medicines are 
often taken outside the health facility without the knowl-
edge and support of healthcare providers.12 48 57 In such 
situations, the risk of adverse events could be higher than 
reported by these studies.
Figure 6 The use of herbal medicines for induction of labour and the incidence of meconium-stained liquor. RR, risk ratio.
Figure 7 The use of herbal medicines for induction of labour and neonatal admission to nursery. RR, risk ratio.
Protected by copyright.
 o
n
 Septem
ber 25, 2019 at The Librarian J B M
orrell Library.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-022499 on 17 October 2018. Downloaded from 
8 Zamawe C, et al. BMJ Open 2018;8:e022499. doi:10.1136/bmjopen-2018-022499
Open access 
Lastly, all studies in this review are from higher and 
UMICs. No study from a low or LMIC was included. This 
probably suggests lack of studies on this subject in limit-
ed-resource settings. Hence, the findings of this review 
cannot be extrapolated beyond higher and UMICs. 
Since the issue of safety of herbal medicines in preg-
nancy relates to maternal as well as neonatal morbidity 
and mortality,22 48 58–60 which are principally the problems 
of LIC,61 62 high-quality studies that include a range of 
maternal morbidity and mortality outcomes in LIC are 
urgently needed.22 63
CONCLUSIONS AND IMPLICATIONS
The evidence from this review suggests that herbal medi-
cines for IOL are effective, but their safety among women 
and neonates require further exploration. Therefore, we 
would not recommend the use of these medicines until 
all the safety concerns are adequately addressed. In the 
meantime, larger safety and efficacy studies with suffi-
cient statistical power and of high methodological quality 
should be conducted to improve the evidence base.
Twitter @czamawe
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